 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1982 | 1 | 0 | 1 | | 1983 | 1 | 0 | 1 | | 1986 | 3 | 2 | 5 | | 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 1 | 4 | | 1991 | 0 | 1 | 1 | | 1992 | 2 | 0 | 2 | | 1994 | 1 | 2 | 3 | | 1995 | 2 | 5 | 7 | | 1997 | 4 | 0 | 4 | | 1998 | 9 | 1 | 10 | | 1999 | 2 | 1 | 3 | | 2000 | 4 | 2 | 6 | | 2001 | 7 | 3 | 10 | | 2002 | 4 | 3 | 7 | | 2003 | 9 | 2 | 11 | | 2004 | 12 | 3 | 15 | | 2005 | 7 | 2 | 9 | | 2006 | 7 | 4 | 11 | | 2007 | 12 | 3 | 15 | | 2008 | 8 | 1 | 9 | | 2009 | 10 | 5 | 15 | | 2010 | 9 | 4 | 13 | | 2011 | 5 | 3 | 8 | | 2012 | 8 | 2 | 10 | | 2013 | 13 | 1 | 14 | | 2014 | 10 | 2 | 12 | | 2015 | 9 | 2 | 11 | | 2016 | 9 | 9 | 18 | | 2017 | 4 | 3 | 7 | | 2018 | 4 | 3 | 7 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, Cobleigh MA. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019 Sep; 177(2):325-333.
-
Paner A, Okwuosa TM, Richardson KJ, Libby EN. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol. 2018 12; 11(12):957-973.
-
Chew W, Benson C, Thway K, Hayes A, Miah A, Zaidi S, Lee ATJ, Messiou C, Fisher C, van der Graaf WT, Jones RL. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
-
Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
-
Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
-
Puglisi MP, Bradaric MJ, Pontikis J, Cabai J, Weyna T, Tednes P, Schretzman R, Rickert K, Cao Z, Andrei D. Novel primary amine diazeniumdiolates-Chemical and biological characterization. Drug Dev Res. 2018 May; 79(3):136-143.
-
Antoniou G, Lee ATJ, Huang PH, Jones RL. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
-
Kanis MJ, Zielenbach M, Karmali R, Peevey J, Blanco LZ, Horowitz JM, Lurain JR. Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. J Low Genit Tract Dis. 2018 Jan; 22(1):82-84.
-
Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, Ryken T, Johnson T, Scullin E. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 04; 7(2):CNS08.
-
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017 Nov 14; 70(20):2536-2551.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|